2020 Azbee Awards of Excellence

Category

All Content > Regular Column, Staff-Written > Mid Atlantic

Awarded to

Jacob Bell, Reporter; Ned Pagliarulo, Senior Editor; Kim Dixon, Managing Editor

Entry details

BioPharma Dive’s Pharmacquired

Issue or publication date: September 5, 2019; July 29, 2019
Publication name: BioPharma Dive
Publishing company: Industry Dive
Website home page: biopharmadive.com

Please describe the publication's mission and readership:

BioPharma Dive covers the pharmaceutical and biotech industries – the deals, clinical trials, regulations and other drivers of news for industry insiders. The mission is to inform, shed light and analyze the biggest topics in the industry and drive the larger conversation about the sector. Our daily newsletter reaches industry leaders from the C-suite of major pharmas to regulatory officials to innovators at promising biotech startups.

Please describe the enterprising work that went into this entry and its significance or impact on readers:

Deals are the lifeblood of the biopharma industry. Pharmacquired is a regular column that digs into what drives the industry's deals and asks what might come next.

The column is leading the coverage of dealmaking in the sector. The column provides the deepest analysis around biopharma dealmaking, featuring exclusive interviews with company CEOs, top Wall Street analysts, lawyers and investors. All Pharmacquired columns are original angles developed by Jacob through interviews as well as his own analysis, and advance the dialogue within the industry.

Each Pharmacquired column has made a strong impact with our readers. They set the bar for the kinds of sources BioPharma Dive can get (Jeffrey Leiden, CEO of $56 billion biotech company Vertex Pharmaceuticals, for example) and readers have come to expect impressive executive and Wall Street interviews in each installment.

Forward-looking stories are tricky, particularly when it comes to something as dynamic as M&A. However, Pharmacquired columns and their overarching conclusions have held up over time. Sanofi, for example, took a $2 billion impairment charge related to its $11 billion buyout of Bioverativ just one month after Jacob detailed how the French pharma would likely need to invest further in hemophilia drugs to keep up with the rapidly evolving market.

Links to entry URLs

Please note: These URLs are only required for entries in the Online division categories, entries in the Design division categories that are specific to websites, entries in the Website of the Year category, and entries in the Cross-Platform Package of the Year category.

Entry URL(s), if applicable:
https://www.biopharmadive.com/news/pharmacquired-vertex-deal-gene-therapy-leiden/562259/
https://www.biopharmadive.com/news/pharmacquired-neuroscience-mergers-acquisitions-takeover-targets-cns/558651/

Links to Uploaded Entry Files

Please note: The links below are the same links as clicking on the Preview images at the top of this column. You may click the links below to view each submitted entry file.

View entry file #1 
View entry file #2 
View entry file #3 
View entry file #4
View entry file #5 
View entry file #6 
View entry file #7 
View entry file #8 
View entry file #9 
View entry file #10